SCHEMBL4154762

SCHEMBL4154762

Cc1[nH]c2c(F)ccc(C)c2c1CCNC(=O)c1cc2cc(F)ccc2s1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ RAB9A P51151 4/20 0.42
▸ NPC1 O15118 3/20 0.42
▸ CLK1 P49759 5/20 0.41
▸ POLB P06746 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ OPRM1 P35372 2/20 0.38
▸ CHRNA7 P36544 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ MAPT P10636 1/20 0.38
▸ HTR3A P46098 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ NAMPT P43490 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ CLK2 P49760 2/20 0.36
▸ ITGB3 P05106 1/20 0.36
▸ ITGA2B P08514 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4146564 0.91 LMNA (0.50) MEN1KMT2ARAB9ANPC1CLK1
SCHEMBL4148979 0.90 MEN1 (0.51) MEN1KMT2ARAB9ACLK1POLB
SCHEMBL13942521 0.89 MEN1 (0.43) MEN1KMT2ARAB9ANPC1CLK1
SCHEMBL4139512 0.87 CLK1 (0.45) MEN1KMT2ACLK1POLBLMNA
SCHEMBL4139647 0.86 F10 (0.45) MEN1KMT2ARAB9ANPC1OPRM1
SCHEMBL4131916 0.85 MEN1 (0.44) MEN1KMT2ARAB9ANPC1CLK1
SCHEMBL4150354 0.84 MEN1 (0.43) MEN1KMT2ARAB9ANPC1CLK1
SCHEMBL13942010 0.81 NPC1 (0.53) MEN1KMT2ARAB9ANPC1POLB
SCHEMBL13942173 0.81 CNR1 (0.53) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL4137005 0.81 KMT2A (0.53) MEN1KMT2APOLBLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US disclosed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US disclosed
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AG (DE) 2009-01-22 — — US disclosed
WO-2008152099-A2 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023741-A1 ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 MEN1 4355/4885KMT2A 1480/4885RAB9A 3569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback